



# Amaxa™ Nucleofector™ Protocol for Human Prostate Epithelial Cells (PrEC)


## For Human Prostate Epithelial Cells (hPrEC)

Validated to work with Clonetics™ PrEC [Lonza; Cat. No. CC-2555]; adherent epithelial cells

### Example for Nucleofection™ of human PrECs



Human PrECs were transfected using program W-001 and a plasmid encoding the green fluorescent protein, maxGFP® Vector. 24 hours post Nucleofection™ the cells were analyzed by light (A) or fluorescence microscopy (B).



Transfection efficiency of hPrECs 24 hours post Nucleofection™. Cells were transfected using program W-001 and 2 µg of pmaxGFP™ Vector.

## Product Description

**Recommended Kit(s):** Basic Nucleofector™ Kit for Primary Mammalian Epithelial Cells

Cat. No.	VPI-1005
Size (reactions)	25
Nucleofector™ Solution	2.25 ml (2.05 ml + 10% overfill)
Supplement	0.5 ml (0.45 ml + 10% overfill)
pmaxGFP™ Vector (0.5 µg/µl in 10 mM Tris pH 8.0)	30 µg
Certified cuvettes	25
Plastic pipettes	25
Storage and stability	Store Nucleofector™ Solution, Supplement and pmaxGFP™ Vector at 4°C. For long-term storage, pmaxGFP™ Vector is ideally stored at -20°C. The expiration date is printed on the solution box. Once the Nucleofector™ Supplement is added to the Nucleofector™ Solution it is stable for three months at 4°C.

## Required Material

**Note** Please make sure that the entire supplement is added to the Nucleofector™ Solution. The ratio of Nucleofector™ Solution to supplement is 4.5 : 1. For a single reaction use 82 µl of Nucleofector™ Solution plus 18 µl of supplement to make 100 µl of total reaction volume.

- Nucleofector™ Device
- Supplemented Nucleofector™ Solution at room temperature
- Supplied certified cuvettes
- Supplied plastic pipettes
- Supplied pmaxGFP™ Vector
- Substrate of interest, highly purified, preferably by using endotoxin free kits; A260 : A280 ratio should be at least 1.8
- **For trypsinization:** Reagent Pack™ Subculture Reagent Kit containing Trypsin/EDTA, HEPES Buffered Saline Solution (HBSS) and Trypsin Neutralizing Solution (TNS) [Lonza; Cat. No. CC-5034]
- Prepared 6-well culture dish
- **Culture medium:** PrEGM® BulletKit [Lonza; Cat. No. CC-3166] per reaction]. We recommend storing 40 ml aliquots of the prepared medium at -80°C. Do not use medium stored at 4°C for more than two days, as this may lead to increased cell mortality and significant reduction of transfection efficiency
- Prewarm appropriate volume of culture media at 37°C (1.5 ml per reaction)
- Appropriate number of cells (5 x 10<sup>5</sup> cells per sample); minimal cell number: 3 x 10<sup>5</sup> cells (a lower cell number may lead to a major increase in cell mortality); maximal cell number: 7 x 10<sup>5</sup> cells

## 1. Pre Nucleofection™

**Note** Transfection results may be donor-dependent.

### Cell culture recommendations

- 1.1 Seeding conditions: 2.5 x 10<sup>3</sup> cells/cm<sup>2</sup>. Use flasks with a surface area of 75 m<sup>2</sup> only. High cell densities in hPrEC culture lead to reduced cell viability and transfection efficiency
- 1.2 Replace medium 1 day after splitting, then every 2 days
- 1.3 Cells should be passaged every 3 – 4 days
- 1.4 For Nucleofection™ cells should be preferably passaged 2 days before
- 1.5 Do not use cells after passage number 8 as this may result in substantially lower gene transfer efficiency and viability
- 1.6 Optimal confluency before Nucleofection™ 60 – 80%

### Trypsinization

- 1.7 Remove media from the cultured cells and wash cells once with HBSS; use at least same volume of HBSS as culture media
- 1.8 For harvesting, incubate the cells 4 – 6 minutes at 37°C with recommended volume of indicated trypsinization reagent (please see required material)
- 1.9 Neutralize trypsinization reaction with TNS once the majority of the cells (>90%) have been detached (latest after 7 minutes as otherwise cells may start to clump)

2. Nucleofection™

**Note** When using self-isolated PrECs or cells obtained from another supplier than Lonza we recommend testing the programs of our basic protocol for primary mammalian epithelial cells: S-005, T-013, T-020, W-001, U-017

One Nucleofection™ Sample contains

5 x 10 <sup>5</sup> cells
1 – 5 µg plasmid DNA (in 1 – 5 µl H <sub>2</sub> O or TE) or 2 µg pmaxGFP™ Vector or 30 – 300 nM siRNA (3 – 30 pmol/sample)
100 µl Nucleofector™ Solution

- 2.1 Please make sure that the entire supplement is added to the Nucleofector™ Solution
- 2.2 Prepare 6-well plates by filling appropriate number of wells with 1.5 ml of supplemented culture media and pre-incubate/equilibrate plates in a humidified 37°C/5% CO<sub>2</sub> incubator
- 2.3 Harvest the cells by trypsinization (please see 1.7 – 1.9)
- 2.4 Count an aliquot of the trypsinized cells and determine cell density
- 2.5 Centrifuge the required number of cells (5 x 10<sup>5</sup> cells per sample) at 220xg for 5 minutes at room temperature
- 2.6 Resuspend the cell pellet carefully in 100 µl room temperature Nucleofector™ Solution per sample
- 2.7 Combine 100 µl of cell suspension with **1 – 5 µg DNA**, 2 µg pmaxGFP™ Vector or **30 nM – 300 nM siRNA** (3 – 30 pmol/sample) or other substrates
- 2.8 Transfer cell/DNA suspension into certified cuvette (sample must cover the bottom of the cuvette without air bubbles). Close the cuvette with the cap
- 2.9 Select the appropriate Nucleofector™ Program **W-001** (**W-01** for Nucleofector™ I Device)
- 2.10 Insert the cuvette with cell/DNA suspension into the Nucleofector™ Cuvette Holder and apply the selected program
- 2.11 Take the cuvette out of the holder once the program is finished
- 2.12 Add ~500 µl of the pre-equilibrated culture media to the cuvette and **gently** transfer the sample into the 6-well plate. Use the supplied pipettes and avoid repeated aspiration of the sample

3. Post Nucleofection™

- 3.1 Incubate the cells in a humidified 37°C/5% CO<sub>2</sub> incubator until analysis. Gene expression is often detectable after only 4 – 8 hours

## Additional Information

For an up-to-date list of all Nucleofector™ References, please refer to:  
[www.lonza.com/nucleofection-citations](http://www.lonza.com/nucleofection-citations)

For more technical assistance, contact our Scientific Support Team:

USA/Canada  
Phone: 800 521 0390 (toll-free)  
Fax: 301 845 8338  
E-mail: [scientific.support@lonza.com](mailto:scientific.support@lonza.com)

Europe and Rest of World  
Phone: +49 221 99199 400  
Fax: +49 221 99199 499  
E-mail: [scientific.support.eu@lonza.com](mailto:scientific.support.eu@lonza.com)

Lonza Cologne GmbH  
50829 Cologne, Germany

Please note that the Amaxa™ Nucleofector™ Technology is not intended to be used for diagnostic purposes or for testing or treatment in humans.

The Nucleofector™ Technology, comprising Nucleofection™ Process, Nucleofector™ Device, Nucleofector™ Solutions, Nucleofector™ 96-well Shuttle™ System and 96-well Nucleocuvette™ plates and modules is covered by patent and/or patent-pending rights owned by Lonza Cologne GmbH.

Amaxa, Nucleofector, Nucleofection, maxGFP, Reagent Pack, PrEGM and BulletKit are either registered trademarks or trademarks of the Lonza Group or its affiliates.

Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at [license@evrogen.com](mailto:license@evrogen.com).

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license.

No statement is intended or should be construed as a recommendation to infringe any existing patent.

© Copyright 2011, Lonza Cologne GmbH. All rights reserved DPK-1003 03/11